(SMG) Scotts Miracle-Gro - NYSE
Sector: Basic Materials | Industry: Agricultural Inputs | Exchange: NYSE (USA) | Market Cap: 3.355m USD | Total Return: 1% in 12m
Avg Turnover: 47.2M
EPS Trend: 81.0%
Qual. Beats: 2
Rev. Trend: -72.0%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
No distinct edge detected
The Scotts Miracle-Gro Company (SMG) is a leading global manufacturer and marketer of consumer lawn and garden care products. Its portfolio spans traditional fertilizers, grass seeds, and pest control under established brands like Scotts, Miracle-Gro, and Ortho. The company also operates a dedicated segment for indoor and hydroponic gardening, providing specialized lighting, nutrients, and filtration systems for professional and hobbyist growers.
Operating within the Fertilizers & Agricultural Chemicals sub-industry, the company utilizes a multi-channel distribution strategy that includes mass merchandisers, home centers, and e-commerce platforms. This sector is characterized by seasonal demand cycles and sensitivity to raw material costs, such as nitrogen and phosphorus. SMG maintains a strategic marketing agreement to serve as the exclusive agent for Monsanto’s consumer Roundup brand, further diversifying its weed control offerings.
You can evaluate the company’s valuation metrics and historical performance trends by exploring ValueRay. Founded in 1868 and headquartered in Marysville, Ohio, the company has expanded from a regional seed business into a diversified agricultural chemical provider with a significant footprint in the emerging hydroponics market.
- Consumer lawn and garden demand fluctuates based on seasonal weather patterns
- Hawthorne segment performance correlates with legal cannabis market growth and oversupply
- Raw material costs for nitrogen and resin impact gross profit margins
- High debt leverage and interest rates influence equity valuation and dividend stability
- Retailer inventory management at Home Depot and Lowes dictates replenishment cycles
| Net Income: 110.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 0.33 > 1.0 |
| NWC/Revenue: 10.22% < 20% (prev 20.73%; Δ -10.51% < -1%) |
| CFO/TA 0.14 > 3% & CFO 478.1m > Net Income 110.9m |
| Net Debt (2.62b) to EBITDA (519.5m): 5.03 < 3 |
| Current Ratio: 1.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.1m) vs 12m ago 1.20% < -2% |
| Gross Margin: 32.48% > 18% (prev 28.00%; Δ 4.48% > 0.5%) |
| Asset Turnover: 97.55% > 50% (prev 97.68%; Δ -0.13% > 0%) |
| Interest Coverage Ratio: 3.85 > 6 (EBIT TTM 450.5m / Interest Expense TTM 117.0m) |
| A: 0.10 (Total Current Assets 1.62b - Total Current Liabilities 1.28b) / Total Assets 3.41b |
| B: 0.10 (Retained Earnings 331.0m / Total Assets 3.41b) |
| C: 0.13 (EBIT TTM 450.5m / Avg Total Assets 3.47b) |
| D: -0.08 (Book Value of Equity -286.5m / Total Liabilities 3.70b) |
| Altman-Z'' = 1.77 = BBB |
| DSRI: 0.98 (Receivables 766.7m/799.3m, Revenue 3.39b/3.45b) |
| GMI: 0.86 (GM 28.00% / 32.48%) |
| AQI: 1.00 (AQ_t 0.34 / AQ_t-1 0.34) |
| SGI: 0.98 (Revenue 3.39b / 3.45b) |
| TATA: -0.11 (NI 110.9m - CFO 478.1m) / TA 3.41b) |
| Beneish M = -3.19 (Cap -4..+1) = AA |
As of June 12, 2026, the stock is trading at USD 61.88 with a total of 517,700 shares traded.
Over the past week, the price has changed by +8.89%,
over one month by +4.24%,
over three months by -0.32% and
over the past year by +0.98%.
Scotts Miracle-Gro has received a consensus analysts rating of 4.36. Therefore, it is recommended to buy SMG.
- StrongBuy: 7
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 72.8 | 17.7% |
P/E Trailing = 16.5718
P/E Forward = 14.0056
P/S = 0.9667
P/B = 21.9459
P/EG = 0.7953
Revenue TTM = 3.39b USD
EBIT TTM = 450.5m USD
EBITDA TTM = 519.5m USD
Long Term Debt = 2.07b USD (from longTermDebt, last quarter)
Short Term Debt = 279.4m USD (from shortTermDebt, last quarter)
Debt = 2.62b USD (from shortLongTermDebtTotal, last quarter) + Leases 273.8m
Net Debt = 2.62b USD (calculated: Debt 2.62b - CCE 6.20m)
Enterprise Value = 5.97b USD (3.36b + Debt 2.62b - CCE 6.20m)
Interest Coverage Ratio = 3.85 (Ebit TTM 450.5m / Interest Expense TTM 117.0m)
EV/FCF = 15.72x (Enterprise Value 5.97b / FCF TTM 379.7m)
FCF Yield = 6.36% (FCF TTM 379.7m / Enterprise Value 5.97b)
FCF Margin = 11.20% (FCF TTM 379.7m / Revenue TTM 3.39b)
Net Margin = 3.27% (Net Income TTM 110.9m / Revenue TTM 3.39b)
Gross Margin = 32.48% ((Revenue TTM 3.39b - Cost of Revenue TTM 2.29b) / Revenue TTM)
Gross Margin QoQ = 41.83% (prev 25.03%)
Tobins Q-Ratio = 1.75 (Enterprise Value 5.97b / Total Assets 3.41b)
Interest Expense / Debt = 4.46% (Interest Expense 117.0m / Debt 2.62b)
Taxrate = 33.14% (105.5m / 318.3m)
NOPAT = 301.2m (EBIT 450.5m * (1 - 33.14%))
Current Ratio = 1.27 (Total Current Assets 1.62b / Total Current Liabilities 1.28b)
Debt / Equity = -9.15 (negative equity) (Debt 2.62b / totalStockholderEquity, last quarter -286.5m)
Debt / EBITDA = 5.03 (Net Debt 2.62b / EBITDA 519.5m)
Debt / FCF = 6.89 (Net Debt 2.62b / FCF TTM 379.7m)
Total Stockholder Equity = -328.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.19% (Net Income 110.9m / Total Assets 3.41b)
RoE = -33.72% (negative equity) (Net Income TTM 110.9m / Total Stockholder Equity -328.9m)
RoCE = 25.90% (EBIT 450.5m / Capital Employed (Equity -328.9m + L.T.Debt 2.07b))
RoIC = 12.50% (NOPAT 301.2m / Invested Capital 2.41b)
WACC = 6.23% (E(3.36b)/V(5.98b) * Re(8.77%) + D(2.62b)/V(5.98b) * Rd(4.46%) * (1-Tc(0.33)))
Discount Rate = 8.77% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 55.56 | Cagr: 1.86%
[DCF] Terminal Value 75.36% ; FCFF base≈380.6m ; Y1≈380.3m ; Y5≈399.0m
[DCF] Fair Price = 61.82 (EV 6.21b - Net Debt 2.62b = Equity 3.60b / Shares 58.2m; r=8.35% [WACC [floored]]; 5y FCF grow -0.58% → 2.50% )
EPS Correlation: 81.03 | EPS CAGR: 79.00% | SUE: 2.13 | # QB: 2
Revenue Correlation: -72.00 | Revenue CAGR: -2.04% | SUE: 1.61 | # QB: 1
EPS current Quarter (2026-06-30): EPS=2.48 | Chg30d=-1.97% | Revisions=-50% | Analysts=7
EPS current Year (2026-09-30): EPS=4.35 | Chg30d=+0.06% | Revisions=+60% | GrowthEPS=+16.2% | GrowthRev=-2.7%
EPS next Year (2027-09-30): EPS=4.70 | Chg30d=-0.42% | Revisions=-14% | GrowthEPS=+8.2% | GrowthRev=+2.6%
[Analyst] Revisions Ratio: +60%